Pathogenesis of HERG Mutations in Human Long QT Syndrome

人类长 QT 综合征中 HERG 突变的发病机制

基本信息

  • 批准号:
    6683227
  • 负责人:
  • 金额:
    $ 26.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-12-05 至 2005-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Congenital long QT syndrome (LQTS) is a disease associated with delayed cardiac repolarization and prolonged QT intervals on the electrocardiogram, which can lead to ventricular arrhythmia with cardiac sudden death. One of the major forms of LQTS (LQT2) is caused by mutations in the human ether-a-go-go-related gene (HERG) that encodes the rapidly activating delayed rectifier potassium channel. To date, more than 100 HERG mutations have been identified in patients with LQTS. Our previous work has shown that a major mechanism for loss of HERG channel function in LQT2 is defective protein trafficking which results in failure of mutant channels to reach the cell surface. We also showed that high affinity HERG channel blockers can correct defective protein trafficking of some LQT2 mutants. The goals of this proposal are (1) to study the mechanisms of defective protein trafficking of LQT2 mutant channels, and (2) to determine how HERO channel blockers rescue trafficking defective LQT2 mutant channels. Our hypotheses are (1) LQT2 mutations cause misfolding or improper assembly of HERO protein which is recognized by quality control system leading to ER retention and degradation by the proteasome, and (2) drugs that bind to HERO channels with high affinity act as pharmacological chaperones to promote proper folding or assembly in a conformation that permits trafficking to the plasma membrane. We will test these hypotheses by four specific aims: aim I to determine whether LQT2 mutations cause misfolding or improper assembly of mutant channels; aim 2 to study the role of molecular chaperones in the ER retention of LQT2 mutant channels; aim 3 to investigate the mechanisms by which LQT2 mutants are recognized and degraded by the proteasome; and aim 4 to elucidate the mechanisms by which high affinity HERG channel blockers correct defective protein trafficking of LQT2 mutant channels. We will use a combination of biochemical, immunohistochemical and patch clamp techniques to study wild type HERG and LQT2 mutant channels expressed in transfected tissue culture cells and in cell-free systems. These studies will strengthen our knowledge of how misfolded and improperly assembled LQT2 mutant channels are recognized, retained and degraded by the ER quality control system and how HERG channel blockers modify these processes and rescue LQT2 mutant channels. Elucidating these mechanisms is an important step towards the development of pharmacological strategies for therapies of congenital LQTS.
描述(由申请人提供):先天性长QT综合征(LQTS)是一种 与心脏复极延迟和QT间期延长相关的疾病 心电图上的间隔,这可能导致室性心律失常 心脏性猝死LQTS的主要形式之一(LQT 2)是由以下原因引起的: 人类ether-a-go-go相关基因(HERG)中的突变,该基因编码 快速激活延迟整流钾通道。迄今为止,超过100 已在LQTS患者中发现HERG突变。我们以前的工作 已经表明LQT 2中HERG通道功能丧失的主要机制是 蛋白质运输缺陷,导致突变通道无法 到达细胞表面。我们还表明,高亲和力HERG通道阻滞剂 可以纠正一些LQT 2突变体的蛋白质运输缺陷。的目标 这一建议是(1)研究缺陷蛋白质运输的机制 LQT 2突变通道,以及(2)确定HERO通道阻滞剂如何拯救 运输缺陷型LQT 2突变体通道。我们的假设是:(1)LQT 2 突变导致HERO蛋白的错误折叠或不正确组装, 质量控制系统认可,导致ER保留和降解, 蛋白酶体,和(2)以高亲和力结合HERO通道的药物起作用 作为药理学分子伴侣,以促进细胞内的正确折叠或组装, 允许运输到质膜的构象。我们将测试 这些假设通过四个具体目标:目标I,以确定是否LQT 2 突变导致突变通道的错误折叠或不正确组装;目的2 研究分子伴侣在LQT 2突变体内质网滞留中的作用 目的3:研究LQT 2突变体通过何种机制, 被蛋白酶体识别和降解;目的4阐明 高亲和力HERG通道阻滞剂纠正缺陷性 LQT 2突变体通道的蛋白质运输。我们将结合使用 生物化学、免疫组织化学和膜片钳技术研究野生型 在转染的组织培养细胞中表达的HERG和LQT 2突变通道, 在无细胞系统中。这些研究将加强我们的知识, 错误折叠和不正确组装的LQT 2突变通道被识别, 保留和降解的ER质量控制系统,以及如何HERG通道 阻断剂修饰这些过程并拯救LQT 2突变通道。阐明 这些机制是发展的重要一步, 治疗先天性LQTS的药理学策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZHENGFENG ZHOU其他文献

ZHENGFENG ZHOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZHENGFENG ZHOU', 18)}}的其他基金

Post-transcriptional regulation of Kv11.1 (hERG) channel expression by alternative splicing and polyadenylation
通过选择性剪接和多聚腺苷酸化对 Kv11.1 (hERG) 通道表达进行转录后调控
  • 批准号:
    10626127
  • 财政年份:
    2022
  • 资助金额:
    $ 26.43万
  • 项目类别:
Post-transcriptional regulation of Kv11.1 (hERG) channel expression by alternative splicing and polyadenylation
通过选择性剪接和多聚腺苷酸化对 Kv11.1 (hERG) 通道表达进行转录后调控
  • 批准号:
    10442308
  • 财政年份:
    2022
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    7229524
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    7624367
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8302318
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    7844826
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8961627
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8452065
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    9243297
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:
Pathogenesis of HERG Mutations in Human Long QT Syndrome
人类长 QT 综合征中 HERG 突变的发病机制
  • 批准号:
    6819737
  • 财政年份:
    2001
  • 资助金额:
    $ 26.43万
  • 项目类别:

相似海外基金

The mechanism of oral carcinogenesis by FAT1 gene mutation
FAT1基因突变导致口腔癌的机制
  • 批准号:
    23K15977
  • 财政年份:
    2023
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an efficient method combining quantum chemistry and machine learning to evolve PCR technology and gene mutation analysis
开发一种结合量子化学和机器学习的有效方法来发展 PCR 技术和基因突变分析
  • 批准号:
    22KJ2450
  • 财政年份:
    2023
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of preemptive medicine for asymptomatic MEN1 gene mutation carriers
无症状MEN1基因突变携带者的抢先治疗药物开发
  • 批准号:
    23H03151
  • 财政年份:
    2023
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidation of molecular mechanisms of occurrence of anaplastic thyroid cancer using gene mutation analysis and comprehensive gene expression analysis
利用基因突变分析和综合基因表达分析阐明甲状腺未分化癌发生的分子机制
  • 批准号:
    23K08067
  • 财政年份:
    2023
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the molecular mechanism of maxillofacial hypoplasia caused by FAT1 gene mutation
FAT1基因突变引起颌面发育不全的分子机制阐明
  • 批准号:
    22K19629
  • 财政年份:
    2022
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Association between CD79B gene mutation and prognosis in vitreoretinal lymphoma
CD79B基因突变与玻璃体视网膜淋巴瘤预后的关系
  • 批准号:
    22K09763
  • 财政年份:
    2022
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene mutation/expression prediction from clinical images using artificial intelligence technology in pancreatic cancer
利用人工智能技术从临床图像预测胰腺癌基因突变/表达
  • 批准号:
    20K17570
  • 财政年份:
    2020
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of colorectal carcinogenesis mediated by PTPRK gene mutation
PTPRK基因突变介导的结直肠癌发生机制的阐明
  • 批准号:
    20K16311
  • 财政年份:
    2020
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the molecular mechanism of development of anaplastic thyroid cancer using gene mutation analysis and comprehensive gene expression analysis
利用基因突变分析和综合基因表达分析阐明甲状腺未分化癌发生的分子机制
  • 批准号:
    20K08953
  • 财政年份:
    2020
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of next-generation precision medicine targeting the pathways on which driver gene mutation-positive lung cancer depends
针对驱动基因突变阳性肺癌所依赖的途径开发下一代精准医疗
  • 批准号:
    20H03771
  • 财政年份:
    2020
  • 资助金额:
    $ 26.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了